Biotech Values

[DewDiligence]

RVNC—Abridged enrollment completed in upper-limb-spasticity phase-2—results early 2021:

https://investors.revance.com/news-releases/news-release-details/revance-announces-last-patient-enrolled-modified-juniper-phase-2

Revance Therapeutics…today announced a decision to complete enrollment in its JUNIPER Phase 2 trial of DaxibotulinumtoxinA for Injection for the treatment of upper limb spasticity in adults after stroke or traumatic brain injury.

Due to ongoing COVID-19 concerns related to subject enrollment and scheduling in-person study visits, the company has chosen to end screening and complete the study with 76 subjects enrolled, along with a few subjects currently being evaluated for participation in the study. The 73 subjects dosed before enrollment was paused in March due to COVID-19 will be followed for up to 36 weeks; subjects enrolled after this will be followed to Week 12. Revance now expects to announce topline data from the JUNIPER Phase 2 trial in early 2021.

RVNC announced on 3/26/20 that enrollment in the JUNIPER study had been paused due to COVID-19 (#msg-154596190).

Note: JUNIPER is entirely separate from the ASPEN-1 and ASPEN-OLS studies in cervical dystionia.